Altair Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• AIR645 · Respiratory/Pulmonology
  AIR645 is an inhaled biologic that targets airway inflammation through a mechanism involving immune modulation in the respiratory tract.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Altair Therapeutics, Inc. portfolio CI brief
• Altair Therapeutics, Inc. pipeline updates RSS